Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
8:00am - 8:55am

Registration

More
Showing of Streams
10:30am - 11:00am

Networking Refreshment Break

More
Showing of Streams
12:30pm - 1:30pm

Networking Luncheon

More
Showing of Streams
3:00pm - 3:30pm

Networking Refreshment Break

More
Showing of Streams
8:00am - 8:55am 55 mins
Registration
8:55am - 9:00am 5 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Chairperson's Remarks
8:55am - 9:00am 5 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
Chairperson's Remarks
8:55am - 9:00am 5 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Chairperson's Remarks
9:00am - 9:30am 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
CMO perspective on vector manufacturing; ensuring supply
9:00am - 9:30am 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
9:00am - 9:30am 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Novel T Cell Approaches
9:30am - 10:00am 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Small biotech considerations – Risk mitigation in ensuring supply of vectors
9:30am - 10:00am 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
9:30am - 10:00am 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Off the shelf CAR-NK cells for Cancer Immunotherapy
10:00am - 10:30am 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Alternatives to viral vectors for gene therapies
10:00am - 10:30am 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
10:00am - 10:30am 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Gamma Delta T cells for the treatment of Cancer
10:30am - 11:00am 30 mins
Networking Refreshment Break
11:00am - 12:00pm 60 mins
Info
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Dual Dialogue: Media supply chain- matching incoming materials to required throughput

Looking for 2 speakers to discuss risk mitigation/scaling up considerations for 2 types of product 

11:00am - 11:30am 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
11:00am - 11:30am 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
CAR Macrophage Immunotherapy to target Solid Tumors
11:30am - 12:00pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
11:30am - 12:00pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
CAR T Combination Therapies
12:00pm - 12:30pm 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Finding a golden standard in chemically defined media; moving away from animal products
12:00pm - 12:30pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
12:00pm - 12:30pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Bispecific CAR-T Cells for Solid Tumor Targeting
12:30pm - 1:30pm 60 mins
Networking Luncheon
1:30pm - 2:30pm 60 mins
Info
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Auto vs. Allo Supply chain considerations; incorporating starting materials into your process
  • Joseph Carosi - Associate Director, Novartis, USA

Looking for one auto and one allo manufacturer to discuss how they are incorporating raw materials into their current process/chain of custody etc. 

1:30pm - 2:00pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
1:30pm - 2:00pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Small Molecule Drugs, Suicide Switches and T Cell Tuners
2:00pm - 2:30pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
2:00pm - 2:30pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Ziopharm Oncology
2:30pm - 3:00pm 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Alternatives to traditional starting materials: Cord Blood
2:30pm - 3:00pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
2:30pm - 3:00pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
CAR-T 2.0 Cell Design Labs (Gilead Case Study) – Synthetic Gene Circuits
3:00pm - 3:30pm 30 mins
Networking Refreshment Break
3:30pm - 4:00pm 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Regulatory considerations concerning continuous supply of raw materials
3:30pm - 4:00pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
3:30pm - 4:00pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
An Innovative Proprietary Off-the-Shelf T-Cell Immunotherapy Technology Platform
4:00pm - 4:30pm 30 mins
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Transportation of materials to manufacturing site: Infrastructure Considerations
4:00pm - 4:30pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
4:00pm - 4:30pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
Feedback on the first FDA approved Allogeneic CAR-T Cell Therapy Trial
4:30pm - 5:00pm 30 mins
Info
Workshop 1- Upstream Supply Chain and Raw Material Considerations
Discussion panel: Supplier qualification and considerations

Looking for 3-5 panelists to discuss supplier qualification, auditing, and different resource for finding raw/starting materials suppliers 

4:30pm - 5:00pm 30 mins
Workshop 2- Bio fabrication – The Path to Commercialization: In collaboration with ARMI
TBC
4:30pm - 5:00pm 30 mins
Workshop 3- Clinical and Early Stage CAR T Cell Advances – Solid Tumours, Combination Therapies and Safety Switches
End of session wrap up and Q&A